SEC Form 4 · accession 0001209191-18-042389
Sarepta Therapeutics, Inc. · SRPT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alexander Cumbo
Officer — SVP, Chief Commercial Officer
Period of report
Jul 9, 2018
Accepted (ET)
Jul 11, 2018 · 6:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000873303
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jul 9, 2018 | M | 11,924 | $13.71 | A | 40,690 | D | |
| Common StockF1 | Jul 9, 2018 | S | 11,924 | $137.32 | D | 28,766 | D | |
| Common StockF1 | Jul 9, 2018 | M | 9,944 | $13.71 | A | 38,710 | D | |
| Common StockF1 | Jul 9, 2018 | S | 9,944 | $137.32 | D | 28,766 | D | |
| Common StockF1 | Jul 9, 2018 | M | 11,914 | $13.90 | A | 40,680 | D | |
| Common StockF1 | Jul 9, 2018 | S | 11,914 | $137.32 | D | 28,766 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $13.71 | Jul 9, 2018 | M | 11,924 | D | Feb 28, 2017 | Feb 28, 2026 | Common Stock | 11,924 | 3,850 | D |
| Stock option (right to buy)F1 | $13.71 | Jul 9, 2018 | M | 9,944 | D | Feb 28, 2017 | Feb 28, 2026 | Common Stock | 9,944 | 3,895 | D |
| Stock option (right to buy)F1 | $13.90 | Jul 9, 2018 | M | 11,914 | D | Feb 27, 2016 | Feb 27, 2025 | Common Stock | 11,914 | 2,250 | D |
Explanation of responses
- F1This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 8, 2018. Accordingly, the reporting person had no discretion with regards to the timing of the transaction.